Therapeutic antibody: new opportunity for immunity and inflammatory diseases.
- Author:
Wei SUN
1
;
Heng LIN
;
Fang HUA
;
Zhuo-wei HU
Author Information
1. Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Antibodies, Monoclonal;
therapeutic use;
Antibodies, Monoclonal, Humanized;
therapeutic use;
Autoimmune Diseases;
therapy;
Graft Rejection;
therapy;
Humans;
Immunosuppressive Agents;
therapeutic use;
Inflammation;
therapy
- From:
Acta Pharmaceutica Sinica
2012;47(10):1306-1316
- CountryChina
- Language:Chinese
-
Abstract:
With the development of therapeutic antibodies over the past decade, they have become the treatment options for immunity and inflammation diseases. Major limitations of mouse antibodies as therapeutic agents - immunogenicity, lack of effectors' functions and short serum half-life -- were subsequently identified and largely overcome by the advent of humanized and fully human antibody technologies. The therapeutic antibodies for immunity and inflammatory diseases are primarily utilized in the treatment of allograft rejection, autoimmune disease, autoinflammatory syndromes, allergies and other chronic inflammation. The action mechanisms of therapeutic antibody include blocking ligands or receptors, regulating receptor activity, clearing the target cells or activating receptor. Strategies for generating the antibody drugs with high efficacy and low side effects can be realized by modulation of Fc-mediated activities and optimization of antigen-binding domains.
